The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.
about
Leflunomide: mode of action in the treatment of rheumatoid arthritisSlow drugs: slow progress? Use of slow acting antirheumatic drugs (SAARDs) in rheumatoid arthritisHydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial.Combination therapy with methotrexate and sulphasalazine in rheumatoid arthritis--tolerance of therapy.Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexateRheumatoid arthritis. New developments in treatment.Medical management of rheumatoid arthritisAdvances and issues in the pharmacotherapy of rheumatoid arthritis.Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugsCombination DMARD therapy for rheumatoid arthritis: a step closer to the goal.Combination of second-line antirheumatic drugs.Rheumatoid arthritis. Designing and implementing a treatment plan.Combination therapy of cyclosporine A with methotrexate or hydroxychloroquine in refractory rheumatoid arthritis.A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis.Excess admixture proportion of extended major histocompatability complex haplotypes of Caucasian origin among rheumatoid arthritis associated haplotypes in African Americans and Afro-Caribbeans.Treatment of Collagen-Induced Arthritis Using Immune Modulatory Properties of Human Mesenchymal Stem Cells.The concomitant use of meloxicam and methotrexate does not clearly increase the risk of silent kidney and liver damages in patients with rheumatoid arthritis.
P2860
Q24675005-8ABEDD85-C98B-4313-B4AD-979F7A8AC7FAQ33564477-AD9FBA58-F1B7-4429-A64D-7D01A66900DBQ33565818-DE50FF2B-56A2-4BBB-96AE-CDF27AF8D464Q33566752-9F239045-A0E8-4D03-AC3B-288F404A8DE8Q36633267-921CFF7E-FC0E-41E1-9DC9-EF7D3F39F28FQ37630862-52222833-BA3B-4D5A-928B-3AB09C657FCBQ40403535-339BE34C-89C8-4445-A98C-62FE0EA0616FQ40434105-31090442-B36E-4574-9732-B05819C7BC69Q41258424-005C83CE-B9AE-4355-860A-FAF33586E35FQ41477754-4D791B64-1698-4939-B7B2-6A0BA13B7984Q41501609-CF446D13-3174-46DF-9D79-779332019D42Q41710477-B9939C5A-4FD9-43B9-82D2-09B2935451ADQ41931766-C55E90B4-A436-4C02-90F5-3EC8876D6AC0Q41938770-E81D0A00-523D-4EAA-AE51-846F29000698Q47833750-722E67CD-7AC1-4AAB-80BE-959A74A5795FQ48240482-C74019A9-45B2-45F3-BAF2-C7A4114F6E09Q54406773-10E34E1A-FBE6-4DFA-97A3-E0FD88718076
P2860
The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of combinations of dis ...... gents in rheumatoid arthritis.
@en
The use of combinations of dis ...... gents in rheumatoid arthritis.
@nl
type
label
The use of combinations of dis ...... gents in rheumatoid arthritis.
@en
The use of combinations of dis ...... gents in rheumatoid arthritis.
@nl
prefLabel
The use of combinations of dis ...... gents in rheumatoid arthritis.
@en
The use of combinations of dis ...... gents in rheumatoid arthritis.
@nl
P356
P1476
The use of combinations of dis ...... gents in rheumatoid arthritis.
@en
P2093
P304
P356
10.1002/ART.1780330116
P577
1990-01-01T00:00:00Z